
|Videos|October 9, 2016
Significant Disparities in Access to Novel Agents For Patients With Melanoma
Author(s)Lidija Kandolf Sekulovic, MD, PhD
Lidija Kandolf Sekulovic, MD, PhD, associate professor of Dermatology, Military Medical Academy in Belgrade, Serbia, discusses a recently published survey during an interview at the 2016 ESMO Congress. The survey found that several thousand patients with metastatic melanoma in Europe do not have access to new, life-saving agents in this field.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
4
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
5



















